Cellarity

Cellarity is pioneering a cell-centric approach to drug discovery, treating disease at the level of cell behavior rather than individual molecular targets. The company's platform uses single-cell technologies and machine learning to digitize cellular behaviors, map the network dynamics governing disease states, and generate medicines that can redirect cell behavior toward health. Backed by Flagship Pioneering, Cellarity has established a partnership with Novo Nordisk for metabolic disease.

$274M

Total raised

Cell-centric drug discovery platform that uses single-cell RNA sequencing, multi-omics, and ML to digitize cell behaviors, model disease at the cellular level, and identify compounds that correct pathological cell states.